Pegulated liposomal doxorubicin and cisplatin given concurrently with conventional radiotherapy: A phase I dose-escalation trial for patients with squamous cell carcinoma of head and neck and lung

Oncology Reports

Volumn 12, Issue 2, 2004, Pages 473-481

  Varveris, H ^a   Kachris, S ^a   Mazonakis, M ^a   Lyraraki, E ^a   Markouizou, A ^b   Karabekios, S ^a   Tzedakis, A ^a   Perisinakis, K ^a   Damilakis, J ^a   Vlachaki, M ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b METAXA Cancer Memorial Hospital   (Greece)

Author keywords

Cisplatin and concurrent irradiation; Liposomal doxorubicin

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; MACROGOL DERIVATIVE;

ADULT; AGED; ARTICLE; CHEMISTRY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; FEMALE; HEAD AND NECK TUMOR; HUMAN; LUNG TUMOR; MALE; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RADIOTHERAPY; SQUAMOUS CELL CARCINOMA; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RADIOTHERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 16544372722     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.2.473     Document Type: Article

References (29)

1. Munro A J: An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 71: 83-91, 1995.
2. Pignon JP, Bourhis J, Domengé C and Designe L: Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Lancet 355: 949-955, 2000.
3. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mytomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 17: 2692-2699, 1999.
4. Byhardt RW, Scott C, Sauce WT, et al: Response, toxicity, failure patterns, and survival in 5 RTOG trials of sequential and/or concurrent chemotherapy and radiation therapy for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 42: 469-478, 1998.
5. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in NSCLC: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311: 809-909, 1995.
6. Harrington KJ, Rowlinson-Busza G, Uster PS, et al: Pegulated liposome encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumors. Cancer Chemother Pharmacol 46: 10-18, 2000.
7. Valdivieso M, Burgess MA, Ewer MS, et al: Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer. A prospective, randomized study. J Clin Oncol 2: 207-214, 1984.
8. Magee MJ, Howard J, Bosl GJ, et al: Phase II trial of 4′-epidoxorubicin in advanced carcinoma of head and neck origin. Cancer Treat Rep 69: 125-126, 1985.
9. Harrington KJ, Mohammadtaghi S, Uster PS, et al: Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegulated liposomes. Clin Cancer Res 7: 243-254, 2001.
10. Koukourakis M, Koukouraki S, Giatromanolaki A, et al : Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small cell lung cancer and head and neck cancer. J Clin Oncol 17: 3512-3521, 1999.
11. Koukourakis M, Romanidis K, Froudarakis M, et al: Concurrent administration of docetaxel and stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer: excellent tolerance using subcutaneous amifostine for cytoprotection. Br J Cancer 87: 385-392, 2002.
12. Caponigro F, Cornelia P, Budillon A, et al: Phase I study of Caelyx (doxorubicin HC1, pegulated liposomal) in recurrent or metastatic head and heck cancer. Ann Oncol 11: 339-342, 2000.
13. Harrington KJ, Lewanski C, Northcote AD, et al: Phase II study of pegulated liposomal doxorubicin (Caelyx™) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cancer 37: 2015-2022, 2001.
14. 2. Ann Oncol 11: 1029-1033, 2000.
15. Bachaud JM, Cohen-Jonathan E, Alzieu C, et al: Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma. Final report of a randomized trial. Int J Radiat Oncol Biol Phys 36: 999-1004, 1996.
16. Saunders M, Dische S, Barrett A, et al: Randomized multicenter trials of CHART vs conventional radiotherapy in head and neck and NSCLC. An interim report. Br J Cancer 34: 315-322, 1996.
17. Hendry JH, Roberts SA, Slevin NJ, et al: Influence of radiotherapy treatment time on control of laryngeal cancer: comparisons between centers in Manchester, UK, and Toronto, Canada. Radiother Oncol 31: 14-22, 1994.
18. Haselow RE, Warshaw MG, Okin MM, et al: Radiation alone vs radiation with weekly low dose cisplatinum in unresectable cancer of the head and neck. In: Head and Neck Cancer. Vol 2. Fee WE, Goepfert H, Johns ME, Strong EW and Ward PH (eds). BC Decker, Toronto, pp279-281, 1990.
19. Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable nonsmall cell lung cncer. N Eng J Med 326: 524-530, 1992.
20. Stewart S and Harrington KJ: The biodistribution and pharmacokinetics of stealth liposomes in patients with solid tumors. Oncology 10 (Suppl 11): 33-37, 1997.
21. World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO Offset Publications, Geneva, 1979.
22. RTOG Late Effects Working Group: LENT SOMA tables. Radiother Oncol 35: 17-60, 1995.
23. Munro AJ, MacDougall RH and Stafford ND: Head and Neck in: Treatment of Cancer. Pat Price and Karol Sikora (eds), Arnold, London, pp314-390, 2002.
24. Varveris H, Delakas D, Anezinis P, et al: Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control. Anticancer Res 17:4771-4780, 1997.
25. Koumantakis E, Haralambakis Z, Koukourakis M, et al: A pilot study of concurrent platinum chemotherapy and intracavitary brachytherapy for locally advanced cancer of the uterine cervix. Br J Radiol 71:552-557, 1998.
26. Varveris H, Mazonakis M, Lyraraki E, et al: A pilot study of preoperative radiotherapy (medium dose rate brachytherapy ± external irradiation) given concurrently to liposome encapsulated doxorubicin and cisplatinum for endometrial carcinoma. Radiother Oncol 56 (Suppl 1): 259, 2000.
27. Varveris H, Mazonakis M, Vlachaki M, et al: A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck. Oncol Rep 10' 185-195, 2003.
28. Harrington KJ, Rowlinson-Busza G, Uster PS, et al: Single fraction irradiation has no effect on uptake of radiolabeled pegulated liposomes in a tumor xenograft model. Int J Radiat Oncol Biol Phys 49: 1141-1148, 2001.
29. Harrington KJ, Rowlinson-Busza G, Syrigos KN, et al: The effect of irradiation on the biodistribution of radiolabeled pegulated liposomes. Int J Radiat Oncol Biol Phys 50: 809-820, 2001.